Kyowa Kirin Co., Ltd. · TSE:4151

Kyowa Kirin — Kyowa Hakko Kirin — Q1 2013 Earnings Presentation

17 slides from Kyowa Kirin's earnings presentation, Apr 24, 2013

  1. Slide 1: FY December 2013 First Quarter

    FY December 2013 First Quarter Reference documents for conference call Kyowa Hakko Kirin Co., Ltd. Executive Managing Officer Kazuyoshi Tachibana April 24, 2013

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This document contains certain forward-looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the pr

  3. Slide 3: Agenda

    AGENDA 1. Summary of 1Q consolidated results 2. Pharmaceuticals business 3. Bio-Chemicals business 4. Development Pipeline 3

  4. Slide 4: Summary of Q1 consolidated results

    Summary of Q1 consolidated results: Analysis of YonY profit changes 4

  5. Slide 5: Q1 net income: Analysis of YonY changes

    Summary of Q1 consolidated results: Analysis of YonY profit changes ¥bn Q1 net income: Analysis of YonY changes Pharmaceuticals - ¥2.9bn 120 12.0 Kyowa Hakko Kirin (non-consol.) -¥4.8bn (technology licensing: Biosimilar related -¥6.0bn, return of Bisulfex development and sales rights+¥2.1bn +1.9 Pro

  6. Slide 6: Summary of Pharmaceuticals business results Q1

    Summary of Pharmaceuticals business results Q1 results: Analysis of YonY profit changes 6

  7. Slide 7: Pharmaceuticals business: Q1 (Consolidated)

    Pharmaceuticals business: Q1 results: Analysis of YonY profit changes (Consolidated) Net sales Operating income ～ ～ ～ ～ FY 12 Q1 67.2 FY 12 Q1 16.7 ～ ～ ～ ～ Domestic sales (parent) +1.8 Gross profits -2.9 Exports (Parent) +0 SG&A, (exc. SG&A, (exc. Technology R&D expenses licensing -3.3 R&D expenses

  8. Slide 8: Sales of core domestic products: Analysis of YonY changes

    Sales of core domestic products: Analysis of YonY changes Pharmaceutical sales affected by NHI drug price revisions and other factors, but core products performed well and in line with plan 2012 2013 Unit: ¥ bn (b) – (a) Causes of changes 1Q (a) 1Q(b) Reduction due to NHI price revisions and Nesp 13

  9. Slide 9: Summary of Bio-Chemicals business results Q1

    Summary of Bio-Chemicals business results Q1 results: Analysis of YonY profit changes 9

  10. Slide 10: Bio-Chemicals business: Q1 (Consolidated)

    Bio-Chemicals business: Q1 results: Analysis of YonY profit changes (Consolidated) Net sales Operating income ～ ～ ～ ～ FY 12 Q1 20.5 FY 12 Q1 1.3 ～ ～ ～ ～ Healthcare (parent) -0.4 Gross profits +0.4 Pharma/ Industrial use +0.3 (Parent) SG&A, (exc. R&D expenses Overseas sales +0.5 -0.2 Dai Ichi Fine -0

  11. Slide 11: Development pipeline

    KYOWA KIRIN Development pipeline copyright© 2008 Kyowa Hakko Kirin Co.,Ltd. All Rights Reserved W

  12. Slide 12: Progress in development pipeline

    Progress in development pipeline Approval for manufacturing and marketing of NOURIAST® (KW-6002), a novel anti-Parkinson’s agent in Japan ・Selective adenosine A2A receptor antagonist. ・First in Class anti-Parkinson’s agent. ・Market size for anti-Parkinson’s agents in Japan: ¥70bn (based on NHI price

  13. Slide 13: Progress in licensing pipeline

    Progress in licensing pipeline KHK4563 (benralizumab ) ・Anti-IL-5 receptor antibody. ・MedImmune is conducting a Phase 2b study in asthma worldwide except Asian countries. ・Kyowa Hakko Kirin is conducting a Phase 2a study in asthma in Japan and Korea. KRN951 (tivozanib) ・A highly selective inhibitor

  14. Slide 14: Appendix

    KYOWA KIRIN Appendix copyright© 2008 Kyowa Hakko Kirin Co.,Ltd. All Rights Reserved 14

  15. Slide 15: Effects of foreign exchange

    Effects of foreign exchange Forex rates 1Q FY2012 1Q FY2013 change /$ ¥79/$ ¥89/$ +¥10/$ /€ ¥104/€ ¥118/€ +¥14/€ /￡ ¥125/￡ ¥141/￡ +¥16/￡ (Period average) Effects of foreign exchange Impact during 1Q /FY2013 Pharmaceuticals Bio-Chemicals Consolidated Business Business Net sales +¥1.7bn +¥1.0bn +¥2.8b

  16. Slide 16: Development progress with outlicensed compounds

    Development progress with outlicensed compounds Phase Name Partner Application Remarks I II III Tivozanib FDA Cancer AVEO (VEGF receptor inhibitor) (KRN951) (Sep. 2012) (KRN951) Cancer KW-2871 Life Science (Anti-GD3 antibody) (Low-fucose antibody) Low-fucose antibody Asthma MEDI-563 MedImmune (Anti-

  17. Slide 17: Inquiries: Corporate Communications Department

    If you have any inquiries regarding this presentation please call: Corporate Communications Department, Kyowa Hakko Kirin Co., Ltd Tel: +81-3-3282-0009

Kyowa Hakko Kirin — Q1 2013 Earnings Presentation on 6ix